Artiva Biotherapeutics (NASDAQ:ARTV) Insider Sells $98,746.22 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) insider Subhashis Banerjee sold 8,222 shares of the company’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $12.01, for a total value of $98,746.22. Following the transaction, the insider directly owned 142,047 shares of the company’s stock, valued at approximately $1,705,984.47. This represents a 5.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Subhashis Banerjee also recently made the following trade(s):

• On Tuesday, August 18th, Subhashis Banerjee sold 429 shares of Artiva Biotherapeutics stock. The stock was sold at an average price of $12.00, for a total value of $5,148.00.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ ARTV opened at $11.31 on Thursday. The stock’s 50-day simple moving average is $10.49 and its 200-day simple moving average is $8.68. The firm has a market capitalization of $552.95 million, a PE ratio of -3.43 and a beta of 2.18. Artiva Biotherapeutics, Inc. has a fifty-two week low of $2.22 and a fifty-two week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.63). On average, sell-side analysts forecast that Artiva Biotherapeutics, Inc. will post -2.62 earnings per share for the current fiscal year.

Institutional Trading of Artiva Biotherapeutics

A number of large investors have recently made changes to their positions in the stock. State of Wyoming purchased a new stake in Artiva Biotherapeutics in the 2nd quarter valued at about $45,000. Prelude Capital Management LLC acquired a new stake in Artiva Biotherapeutics in the third quarter valued at approximately $41,000. Bank of America Corp DE boosted its stake in shares of Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Artiva Biotherapeutics during the 1st quarter valued at $131,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Artiva Biotherapeutics during the 4th quarter worth $91,000.

Analysts Set New Price Targets

A number of research analysts recently commented on ARTV shares. HC Wainwright increased their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Wedbush lifted their price objective on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. Wall Street Zen raised Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Needham & Company LLC restated a “buy” rating and set a $41.00 target price on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.